Remove Outcomes Remove Stroke Remove Wellness
article thumbnail

Don’t Use Lytics in Mild Stroke, Part 3

EM Literature of Note

Well, PRISMS demonstrated unfavorable results. MARISS tried to ascertain predictors of poor outcome in mild stroke, and intravenous thrombolysis was not associated with an effect on the primary outcome. Now, again, we examine thrombolysis in “mild” stroke, in this case, NIHSS ≤3 – and fail.

Stroke 112
article thumbnail

The ARAMIS Trial: DAPT vs Alteplase in Minor Nondisabling Acute Ischemic Stroke

RebelEM

Background: Current stroke guidelines recommend IV alteplase for patients with acute ischemic stroke presenting within 4.5hrs of symptom onset based on the NINDS and ECASS III publications. Both NINDS and ECASS III excluded patients with mild stroke symptoms but failed to clearly define a threshold for mild stroke.

Stroke 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

52 in 52 – #38: Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke

EMDocs

This week we cover the EXTEND trial looking at thrombolysis up to 9 hours after stroke onset. and 9 hours after onset of symptoms, with non-infarcted brain tissue, does the administration of alteplase improve functional outcome at 90 days? Intervention: Alteplase 0.9 in alteplase group versus 0.9% to 53.54, p=0.053).

Stroke 78
article thumbnail

A discussion with interventional cardiologist Dr David Cohen on medical evidence, TAVR and stroke prevention

Sensible Medicine

The other unbelievable thing about TAVR is that strokes are less common than you’d think. Well, there is less debris than I would have thought. Early studies show that the device catches debris that would have occluded blood vessels in the brain—iow, caused stroke. lower rate of stroke in the treatment arm.

Stroke 77
article thumbnail

Non-significant Studies Can Teach A Lot

Sensible Medicine

Many doctors believe that closing the left atrial appendage (with a device) will help reduce stroke and bleeding. The idea behind stroke reduction is that occluding the appendage takes away a common area where clots form. This study report included only 45-day outcomes. This is a decidedly bad outcome. Pause there.

Stroke 132
article thumbnail

Major Trial in Atrial Fibrillation Stopped Prematurely

Sensible Medicine

That means reducing events caused by clots—like stroke. The OCEANIC AF trial enrolled patients with AF who had stroke risk factors. The primary outcome was stroke or systemic embolism. But, ultimately, a new medical intervention has to improve an important outcome as well as or better than standard care.

Stroke 110
article thumbnail

52 in 52 – #40: DIRECT MT – Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke

EMDocs

Inclusion criteria: Enrolled patients over the age of 18 with acute ischemic stroke with CTA confirmed occlusion of ICA, or M1 or M2 segment of MCA Within 4.5 1.40) No statistically significant difference in secondary outcomes No significant difference in safety outcomes Death 18% vs. 19%, RR 0.94 (0.68-1.30)

Stroke 67